Drug intelligence / Profile preview

HIP1502

Development stage: Phase 1
Lead developer: Korea University Anam Hospital
Modality: Small Molecules
Administration: Oral

Overview

HIP1502 is a novel salt formulation of varenicline, specifically varenicline oxalate, being developed by Korea University Anam Hospital for the treatment of nicotine dependence. As a partial agonist of the α4β2 nicotinic acetylcholine receptor subtype, it works by reducing the symptoms of nicotine withdrawal and decreasing the rewarding effects of smoking. HIP1502 is designed as an alternative to the standard varenicline tartrate formulation (marketed as Chantix/Champix), with clinical investigations focusing on its pharmacokinetic profile, safety, and tolerability in healthy subjects to support its use in smoking cessation therapy.

Other names: varenicline oxalate

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on HIP1502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIP1502.

Explore the full profile